Adding Selumetinib to Docetaxel Doesn't Up PFS in NSCLC

Share this content:
Adding Selumetinib to Docetaxel Doesn't Up PFS in NSCLC
Adding Selumetinib to Docetaxel Doesn't Up PFS in NSCLC

WEDNESDAY, May 10, 2017 (HealthDay News) -- The addition of selumetinib to docetaxel does not improve progression-free survival among patients with previously treated advanced KRAS-mutant non-small-cell lung cancer (NSCLC), according to a study published in the May 9 issue of the Journal of the American Medical Association.

Pasi A. Jänne, M.D., from the Dana-Farber Cancer Institute in Boston, and colleagues conducted a multicenter randomized trial across 25 countries involving 510 patients with advanced KRAS-mutant NSCLC. Disease progression following first-line anticancer therapy was assessed. Patients were randomized to selumetinib + docetaxel or placebo + docetaxel (251 and 254 patients, respectively, received treatment).

The researchers found that 88 percent of patients had experienced a progression event at the time of data cut-off, and deaths had occurred in 68 percent. For selumetinib + docetaxel and placebo + docetaxel, median progression-free survival was 3.9 and 2.8 months, respectively (difference, 1.1 months; hazard ratio, 0.93; 95 percent confidence interval, 0.77 to 1.12; P = 0.44). The corresponding overall survival rates were 8.7 and 7.9 months (difference, 0.9 months; hazard ratio, 1.05; 95 percent confidence interval, 0.85 to 1.30; P = 0.64). The objective response rates were 20.1 and 13.7 percent, respectively (difference, 6.4 percent; odds ratio, 1.61; 95 percent confidence interval, 1.00 to 2.62; P = 0.05).

"Among patients with previously treated advanced KRAS-mutant non-small-cell lung cancer, addition of selumetinib to docetaxel did not improve progression-free survival compared with docetaxel alone," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including AstraZeneca, which funded the study. Roche Molecular Systems provided management in testing the formalin-fixed, paraffin-embedded tissue samples.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Risk for Interval CRC Higher in Blacks Than Whites

Risk for Interval CRC Higher in Blacks Than ...

Differences most pronounced for cancer of the distal colon and the rectum

Even Small Amounts of Alcohol Can Affect Breast Cancer Risk

Even Small Amounts of Alcohol Can Affect Breast ...

Small glass of wine each day can up odds of both premenopausal and postmenopausal breast cancer

ATS: Angiotensin II Improves BP in Vasodilatory Shock

ATS: Angiotensin II Improves BP in Vasodilatory Shock

Angiotensin II effective for vasodilatory shock in patients not responding to conventional vasopressors

is free, fast, and customized just for you!

Already a member?

Sign In Now »